England’s NICE Says No To Santhera’s DMD Drug Agamree Due To ‘Unreliable Modeling’

Santhera Pharmaceuticals did not provide enough evidence to demonstrate that its Duchenne muscular dystrophy drug Agamree was a cost-effective use of resources, according to draft guidance from England’s health technology assessment body, NICE.